.svg)
.jpg)
Nearly 50% of newly developed drug candidates that progress to the formulation stage exhibit poor water solubility. For an otherwise promising API, this can limit dissolution and systemic exposure before conventional oral formulation development has progressed very far.
Solubility is only one developability risk. Low permeability, instability, high dose requirements, or a narrow therapeutic window can also make an API difficult to translate into a viable drug product. Pharmaceutical R&D helps identify these constraints early, determine which ones are critical to feasibility, and select a formulation strategy around the actual behaviour of the API.
For high-risk candidates, early assessment can prevent extensive development around an approach that was unlikely to succeed.
A formulation candidate becomes high-risk when one or more API or product characteristics create significant uncertainty around exposure, stability, manufacturability, or administration.
The presence of a risk does not automatically require a complex formulation technology. The first task is to establish how significant that risk is for the intended product.
Pre formulation studies provide the evidence needed to make that distinction.
Rather than choosing a formulation technology first, development teams can characterise the API across four key areas:
These findings allow risks to be prioritised according to their likely impact on product feasibility.
A moderate solubility limitation, for example, may still be manageable within a conventional immediate-release formulation. A poorly soluble, high-dose API with additional stability constraints may require a very different development pathway.
Formulation technologies should address a demonstrated development constraint rather than add complexity without a clear purpose.
For poorly soluble APIs, Pharmaceutical R&D may evaluate particle engineering, amorphous solid dispersions, salts, co-crystals, lipid-based systems, or complexation. The appropriate option depends on the API, dose, and required product profile.
Where conventional release cannot provide the intended exposure profile, modified-release approaches may be considered to control drug release, extend exposure, or manage peak concentrations.
Administration requirements can create a different challenge. Swallowability, taste or the need for convenient dosing may support formats such as:
The dosage form should still solve a genuine product requirement. If a conventional tablet can meet the required performance, stability, and administration objectives, additional formulation complexity may provide little development value.
For products where an oral film is being considered, formulation capability, scale-up experience and manufacturing compatibility become particularly relevant when selecting a development partner. These considerations are explored further in Choosing the Right Pharmaceutical Partner for Oral Film Research & Development.
Not every technically interesting formulation candidate should continue through development.
Clear feasibility criteria can make early Pharmaceutical R&D more decisive. Before extensive optimisation, teams can establish minimum requirements for parameters such as dissolution, stability, dosage-unit size, and manufacturability.
A practical approach can include:
This is particularly important for high-risk candidates. Repeatedly optimising the same formulation is not necessarily de-risking if the underlying limitation remains unresolved.
Some formulation challenges require technologies or analytical capabilities that are not available within every development organisation.
Specialised capabilities may include spray drying, hot-melt extrusion, nanomilling, lipid-based formulation, or controlled-release technologies. Analytical techniques such as X-ray powder diffraction (XRPD), DSC, stability-indicating methods, and biorelevant dissolution testing can provide further insight into difficult formulation behaviour.
External development partnerships can therefore fill specific capability gaps. A pharmaceutical company in India with integrated capabilities, for example, may combine formulation and analytical development with scale-up and manufacturing capabilities within the same development network.
Similarly, pharmaceutical contract manufacturing can extend beyond production capacity when the partner also provides formulation development, analytical support, stability studies, process development, and technology transfer.
For high-risk candidates, the relevant question is not simply whether a partner can manufacture the eventual product. It is whether the required scientific, analytical, and process capabilities are available to establish a viable route to manufacturing in the first place.
ZIM Laboratories is a research-driven pharmaceutical company in India that combines formulation R&D with differentiated drug delivery and manufacturing capabilities across oral dosage forms. Its capabilities include granules, pellets, taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
For formulation candidates requiring more than a conventional development pathway, this integrated capability can support evaluation, formulation development, and progression towards scalable manufacturing.
High-risk formulation candidates do not necessarily require the most complex technology available. They require the right evidence early enough to make the right development decision.
By characterising API risks, testing appropriate formulation strategies and defining feasibility criteria early, Pharmaceutical R&D can distinguish challenges that can be engineered around from those that require a different pathway.
For pharmaceutical companies, that distinction can direct R&D investment towards candidates and formulation approaches with a credible path to commercial manufacturing.
ZIM Laboratories Limited is a therapy-agnostic and innovative drug delivery solution provider focusing on enhancing patient convenience and treatment adherence to drug intake. We offer a range of technology-based drug delivery solutions and non-infringing proprietary manufacturing processes to develop, manufacture, and supply innovative and differentiated generic pharmaceutical products to our customers globally. At ZIM Labs, we provide our customers with a comprehensive range of oral solid value-added, differentiated generic products in semi-finished and finished formulations. These include granules, pellets (sustained, modified, and extended-release), taste-masked powders, suspensions, tablets, capsules, and Oral Thin Films (OTF).
